Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GROINSS-V III
2023-508722-99-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of cisplatin and carboplatin in Vulval carcinoma (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Groin recurrences. Planned start Mar 2024; status: authorised.
02
Drugs
cisplatincarboplatin
03
Conditions
Vulval carcinoma
Beyond the preview
Go deeper on 2023-508722-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508722-99-00.